Frazier Life Sciences Management’s Elevation Oncology ELEV Stock Holding History

Frazier Life Sciences Management’s Portfolio ELEV Stock Details ELEV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-5,993,579	Closed	-$2.2M	–	50
2025 Q2	$2.2M	Hold	5,993,579	–	–	0.09%	49
2025 Q1	$1.55M	Hold	5,993,579	–	–	0.07%	47
2024 Q4	$3.37M	Hold	5,993,579	–	–	0.14%	49
2024 Q3	$3.6M	Buy	5,993,579 +3,035,000	+103%	+$4.5M	0.14%	48
2024 Q2	$7.99M	Buy	+2,958,579	New	+$11.1M	0.37%	38

Other funds holding ELEV

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Frazier Life Sciences Management's ELEV Position: Q3 2025 in Review

Frazier Life Sciences Management sold out of Elevation Oncology (ELEV) in Q3 2025, closing a stake of 5,993,579 shares — an estimated $2.2M sold.

Frazier Life Sciences Management first reported a position in ELEV in Q2 2024 and held it in 5 quarters. The position peaked at $7.99M in Q2 2024. 1 fund tracked by Wall St. Rank holds ELEV as of Q3 2025.

Frazier Life Sciences Management reported no remaining Elevation Oncology position as of Q3 2025 after selling out during the quarter.
Frazier Life Sciences Management sold 5,993,579 Elevation Oncology shares in Q3 2025, an estimated $2.2M.
Frazier Life Sciences Management first reported a position in Elevation Oncology in Q2 2024 and held it in 5 quarters.
Frazier Life Sciences Management's Elevation Oncology position peaked at $7.99M in Q2 2024.
1 fund tracked by Wall St. Rank held Elevation Oncology as of Q3 2025.

Based on Frazier Life Sciences Management's 13F filing for Q3 2025, filed 14 Nov 2025.